CaMKI is more highly expressed in stage III and IV endometrial carcinomas, when compared to stage I and II, and is associated with proliferating cellular nuclear antigen (PCNA)-labelling, clinical state, histological grade, and the presence of invasion, indicating that CaMKI may play a role in endometrial carcinoma progression [94]. Here, CAMK1 is linked to endometrial carcinoma.